Naoki Fukuda

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 11

Top Topics

Ejection Fraction

Small Cell Lung Cancer

Epidermal Growth Factor Receptor

Top Venues

Endocrine journal

Cancer management and research

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine journal 71 (4) (2024)
Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine journal 71 (4) (2024)
Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine journal (2024)
Naoki Fukuda, Kazuhisa Toda, Hirotaka Suto, Ryosuke Oki, Xiaofei Wang, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocrine journal 71 (4) (2024)
Naoki Fukuda, Yoshinori Tanizawa, Kenichi Nakamura, Yui Okada, Grace Segall, Urpo Kiiskinen, Nicolas Fasnacht, Isaac Sanderson, Alex Rider, Katie Lewis
Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan. Future oncology (London, England) (2023)
Naoki Fukuda, Kazuhisa Toda, Shohei Udagawa, Akihiro Ohmoto, Ryosuke Oki, Hirotaka Suto, Xiaofei Wang, Naomi Hayashi, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients. Endocrine 76 (1) (2022)
Naoki Fukuda, Shunji Takahashi
Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. Cancers 13 (9) (2021)
Naomi Hayashi, Yasuyoshi Sato, Yu Fujiwara, Naoki Fukuda, Xiaofei Wang, Kenji Nakano, Testuya Urasaki, Akihiro Ohmoto, Makiko Ono, Junichi Tomomatsu, Yukiko Sato, Hiroki Mitani, Takashi Toshiyasu, Shunji Takahashi
Clinical Impact of Cachexia in Head and Neck Cancer Patients Who Received Chemoradiotherapy. Cancer management and research 13 (2021)
Yasuyoshi Sato, Kenji Nakano, Xiaofei Wang, Naoki Fukuda, Tetsuya Urasaki, Akihiro Ohmoto, Naomi Hayashi, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, Masanori Saito, Yusuke Minami, Keiko Hayakawa, Yuki Funauchi, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Shunji Takahashi
Pre-Treatment Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Marker of Pazopanib Treatment for Soft-Tissue Sarcoma. Cancers 13 (24) (2021)
Naoki Fukuda, Mayu Yunokawa, Yu Fujiwara, Xiaofei Wang, Akihiro Ohmoto, Naomi Hayashi, Tetsuya Urasaki, Yasuyoshi Sato, Kenji Nakano, Makiko Ono, Junichi Tomomatsu, Hiroki Mitani, Shunji Takahashi
Comparison of the efficacy and safety of the EXTREME regimen for treating recurrent or metastatic head and neck squamous cell carcinoma in older and younger adult patients. Cancer reports (Hoboken, N.J.) 4 (2) (2020)
Naoki Fukuda, Yu Fujiwara, Xiaofei Wang, Akihiro Ohmoto, Tetsuya Urasaki, Naomi Hayashi, Yasuyoshi Sato, Kenji Nakano, Mayu Yunokawa, Makiko Ono, Junichi Tomomatsu, Shunji Takahashi
Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 278 (8) (2020)